The negative P/E carries no analytical content here, so the valuation debate reduces to whether a 3.42x book multiple is defensible when the book itself is largely cash raised from shareholders rather than accumulated earnings. HYMC's ROE of -10.7% in 2026Q3 sits far below the 10.5%-19.5% range across HL, CDE, PAAS and AG, which implies investors are paying a producing-peer multiple for a return profile that is structurally negative. This premium appears to be a liquidity-plus-optionality valuation, and it would compress quickly if the cash balance eroded without a definitive feasibility milestone.

With no revenue line, the only profitability signal is the loss trajectory, and per HYMC's reported statements the operating loss reached $28.2M in 2026Q3 as SG&A expanded to $16.7M alongside $8.3M of R&D-type spend. The reported net loss also overstates cash strain in some quarters and understates it in others, since stock-based compensation addbacks of $12.8M in 2026Q3 flatter operating cash flow relative to the -$26.1M net loss. Investors should treat the entire cost base as pre-revenue overhead and technical work, meaning margin analysis becomes meaningful only after commissioning, not before.

The divergence between a stable-looking ROA and an exploding negative ROIC suggests the capital base against which returns are measured has shrunk materially, which is consistent with debt retirement and asset write-downs rather than any compounding of value. ROE of -10.7% against ROA of -9.1% in 2026Q3 confirms leverage is contributing essentially nothing to returns, so there is no financial-engineering offset to the operating drag. Compared to the positive, mid-teens ROICs reported by HL, CDE and PAAS, HYMC's return profile marks it as a capital-consuming development vehicle, and the trend warrants monitoring for stabilization before any return-based valuation is credible.

Coverage ratios of -12.10 in 2025Q4 and -1.66 in 2025Q3 reflected debt costs carried against operating losses, and the disappearance of meaningful coverage data after the deleveraging confirms there is no fixed-charge burden left to test. That removes near-term covenant and refinancing risk entirely, but it also means the balance sheet offers no cushion against dilution: with $47.0M of total liabilities against $237.6M of equity and a cash-funded burn, future funding almost certainly comes from issuance. Relative to peers carrying D/E of 0.10-0.42 with positive operating cash flow, HYMC's zero leverage is a sign of constrained access rather than balance-sheet strength.

A 13.5x current ratio is nominally fortress-like, but because current assets are dominated by cash drawn from equity raises and current liabilities are modest, the ratio measures runway rather than operational resilience. Cumulative free cash outflows of approximately $162.0M over ten quarters against a reported $211.2M cash balance imply a runway measured in low single-digit years absent new funding, so the narrowing from the 2026Q1 peak is the more informative trend than the absolute level. Under a stress scenario in which the exploration program runs longer than planned, liquidity would hold in the accounting sense while economic value erodes, which is why the burn trajectory matters more than the current ratio here.